The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development
Open accessAbstract
Hepatitis B surface antigen (HBsAg) seroclearance occurs rarely in the natural history of chronic hepatitis B (CHB) infection and is associated with a reduced risk of hepatocellular carcinoma (HCC). Many factors are associated with HBsAg seroconversion, including immune, and viral factors. However, the immune mechanisms associated with HBsAg seroclearance are still difficult to elucidate. The aim of the treatment of hepatitis B virus (HBV) infection is the seroclearance of HBsAg. Unfortunately, this goal is rarely reached with current approved treatments. Understanding HBsAg loss mechanisms appears important to achieve an HBV cure drug development. While studies from HBV animal models are giving insights on the potential immune mechanisms and interactions occurring between the immune system and HBsAg, they do not recapitulate all features of CHB in human and are subject to variability due to their complexity. In this article, we review recent studies on these immune factors, their influence on CHB progression, and HBsAg seroconversion. These data provide new insights in the development of immune therapeutic approaches to partially restore the anti-HBV immune response. Targeting HBsAg will ideally relieve the immunosuppressive effects on the immune system and help to restore anti-HBV immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
Human dendritic cell subsets: an update
Collin, M., & Bigley, V. (2018) · Immunology · doi:10.1111/imm.12888 · Cited by 1,301
Resident human hepatitis lymphocytes are phenotypically different from circulating lymphocytes
Norris, S., Collins, C., Doherty, D. G., Smith, F., McEntee, G., Traynor, O., Nolan, N., Hegarty, J., & O'Farrelly, C. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80206-7 · Cited by 374
Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion
Peppa, D., Gill, U. S., Reynolds, G., Easom, N. J. W., Pallett, L. J., Schurich, A., Micco, L., Nebbia, G., Singh, H. D., Adams, D. H., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121172 · Cited by 342
Li, H., Zhai, N., Wang, Z., Song, H., Yang, Y., Cui, A., Li, T., Wang, G., Niu, J., Crispe, I. N., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314098 · Cited by 161
Cited by
Razavi-Shearer, D., Gamkrelidze, I., Pan, C., Jia, J., Berg, T., Gray, R., Lim, Y.-S., Chen, C.-J., Ocama, P., Desalegn, H., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00197-8 · Cited by 441
Self-citationEfficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
Yuen, M.-F., Lim, S.-G., Plesniak, R., Tsuji, K., Janssen, H. L. A., Pojoga, C., Gadano, A., Popescu, C. P., Stepanova, T., Asselah, T., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210027 · Cited by 280
Self-citationGalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases
Qin, Z.-X., Zuo, L., Zeng, Z., Ma, R., Xie, W., Zhu, X., & Zhou, X. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2466767 · Cited by 32
Zeng, Y., Huang, J., Pang, J., Pan, S., Wu, Y., Jie, Y., Li, X., & Chong, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1330644 · Cited by 9
Liu, Z., Li, G., Li, X., Wang, Y., Liao, L., Yang, T., Han, C., Huang, K., Chen, C., Li, X., et al. (2025) · Antiviral Research · doi:10.1016/j.antiviral.2025.106093 · Cited by 7
Metadata
- Authors
- Tout, I., Loureiro, D., Mansouri, A., Soumelis, V., Boyer, N., & Asselah, T.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 73
- Issue
- 2
- Pages
- 409-422
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3017499363
- Cited by
- 162
- References
- 6
- FWCI
- 13.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development. https://app.cochat.ai/papers/10.1016/j.jhep.2020.04.013
- The paper
- Tout, I., Loureiro, D., Mansouri, A., Soumelis, V., Boyer, N., & Asselah, T. (2020). Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.04.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.